ArticlePloS one2011
A new extensively characterised conditionally immortal muscle cell-line for investigating therapeutic strategies in muscular dystrophies.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Validation of positional candidates Rps6ka6 and Pou3f4 for a locus associated with skeletal muscle mass variability.G3 (Bethesda, Md.) · 2024Article
- LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model.Disease models & mechanisms · 2023Article
- Immortalization Reversibility in the Context of Cell Therapy Biosafety.International journal of molecular sciences · 2023Review
- Conditionally immortalised equine skeletal muscle cell lines forBiochemistry and biophysics reports · 2023Article
- MyoD-induced reprogramming of human fibroblasts and urinary stem cellsFrontiers in physiology · 2023Article
- Growth hormone secretagogues modulate inflammation and fibrosis inFrontiers in immunology · 2023Article
- RNA-Seq analysis of a Pax3-expressing myoblast clone in-vitro and effect of culture surface stiffness on differentiation.Scientific reports · 2022Article
- Dystrophin involvement in peripheral circadian SRF signalling.Life science alliance · 2021Article
- Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease.Molecular therapy. Methods & clinical development · 2020Article
- A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.EMBO reports · 2019Article
- Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display.Journal of nanobiotechnology · 2018Article
- SMAD6 overexpression leads to accelerated myogenic differentiation of LMNA mutated cells.Scientific reports · 2018Article
- A real-time monitoring platform of myogenesis regulators using double fluorescent labeling.PloS one · 2018Article
- piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts.Nucleic acids research · 2016Article
- A thin layer angiogenesis assay: a modified basement matrix assay for assessment of endothelial cell differentiation.BMC cell biology · 2014Article
- Identification and validation of quantitative PCR reference genes suitable for normalizing expression in normal and dystrophic cell culture models of myogenesis.PLoS currents · 2014Article
- Restoration of dystrophin expression using the Sleeping Beauty transposon.PLoS currents · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A new conditionally immortal satellite cell-derived cell-line, H2K 2B4, was generated from the H2K(b)-tsA58 immortomouse. Under permissive conditions H2K 2B4 cells terminally differentiate in vitro to form uniform myotubes with a myogenic protein profile comparable with freshly isolated satellite cells. Following engraftment into immunodeficient dystrophin-deficient mice, H2K 2B4 cells regenerated host muscle with donor derived myofibres that persisted for at least 24 weeks, without forming tumours. These cells were readily transfectable using both retrovirus and the non-viral transfection methods and importantly upon transplantation, were able to reconstitute the satellite cell niche with functional donor derived satellite cells. Finally using the Class II DNA transposon, Sleeping Beauty, we successfully integrated a reporter plasmid into the genome of H2K 2B4 cells without hindering the myogenic differentiation. Overall, these data suggest that H2K 2B4 cells represent a readily transfectable stable cell-line in which to investigate future stem cell based therapies for muscle disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.